Management Team

Christopher A. Kroeger, M.D.
President and Chief Executive Officer

Dr. Kroeger was appointed President and Chief Executive Officer in 2008, having served on the company's Board of Directors since 2006. He brings a unique combination of commercial, clinical, scientific and entrepreneurial finance expertise to Cardioxyl. Prior to joining the company, Dr. Kroeger led the biopharmaceutical and medical device investing efforts for the Aurora Funds, where he was involved in the board governance and/or strategic oversight of over a dozen venture backed drug and medical device companies. He currently sits on the boards of CardioFocus, Hyperbranch Medical Technologies, Neotropix and Paringenix. Previously, Dr. Kroeger trained in General Surgery at Brigham and Women's Hospital in Boston. Dr. Kroeger earned his MBA from Harvard Business School, his M.D. from Stanford University School of Medicine, and his BS from Harvard University.


Nitroxyl Technology

Cardioxyl has developed proprietary expertise in the biology, physiology and chemistry of nitroxyl donors

View More

Our Mission

Cardioxyl's mission is to realize the potential of nitroxyl technology through the development of novel therapies that improve the health and quality of life of patients with serious cardiovascular disease.